Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

Andrey · November 24, 2016, 10:07am

ncbi.nlm.nih.gov

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.

C Rohleder, JK Müller, B Lange and FM Leweke, Frontiers in pharmacology, 2016

There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetrahydrocannabinol (Δ9-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. Although, results from animal studies are inconsistent to a certain extent and seem to depend on behavioral paradigms, treatment duration and experimental conditions applied, cannabidiol has shown antipsychotic properties in both rodents and rhesus monkeys. After some individual treatment attempts, the first randomized, double-blind controlled clinical trial demonstrated that in acute schizophrenia cannabidiol exerts antipsychotic properties comparable to the antipsychotic drug amisulpride while being accompanied by a superior, placebo-like side effect profile. As the clinical improvement by cannabidiol was significantly associated with elevated anandamide levels, it appears likely that its antipsychotic action is based on mechanisms associated with increased anandamide concentrations. Although, a plethora of mechanisms of action has been suggested, their potential relevance for the antipsychotic effects of cannabidiol still needs to be investigated. The clarification of these mechanisms as well as the establishment of cannabidiol's antipsychotic efficacy and its hopefully benign side-effect profile remains the subject of a number of previously started clinical trials.

far_cry0 · November 24, 2016, 10:12am

We don’t know until G.W Drugs comes out…??? have to wait…!!!

Green · November 24, 2016, 10:36am

It’s pretty much what I’ve heard before. Just have to see how GW does and what research they come up with. Would be great if it works, cbd can work for some and might not work for everyone at the moment. Maybe if they tinker with different cannabinoids like CBD CBN CBC etc, etc, then maybe that will give different theaputic effects. Just as long as my heart doesn’t get paranoid from it . It could be interesting, but it simply might not work for you.

Topic		Replies	Views
A systematic review of the antipsychotic properties of cannabidiol News	2	844	February 13, 2015
CBD? Does it help? Medications	1	683	September 25, 2016
Question. Is CBD an antipsychotic in your opinion Medications	53	5059	January 24, 2018
Cannabidiol as a potential treatment for psychosis News	3	363	November 21, 2019
Cannabidiol as an Adjunctive Treatment for Schizophrenia News	1	331	April 16, 2019

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

Related topics